Cargando…
The Trend of IgG and IgM Antibodies During 6-Month Period After the Disease Episode in COVID-19 Patients
SARS-CoV-2 is a newly emerged coronavirus that has been widely transmitted since late 2019. It has caused a pandemic and infected roughly 450 million people globally.Hitherto, there is no approved anti-COVID-19 treatment, and vaccination is the only experienced preventive strategy. It mainly promote...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702912/ https://www.ncbi.nlm.nih.gov/pubmed/36466050 http://dx.doi.org/10.1007/s40995-022-01382-7 |
_version_ | 1784839751049674752 |
---|---|
author | Ghasemi, Darioush Araeynejad, Faridoddin Maghsoud, Omid Gerami, Nafiseh Keihan, Amir Homayoun Rezaie, Ehsan Mehdizadeh, Saber Hosseinzadeh, Ramin Mohammadi, Ramtin Bahardoust, Mansour Heiat, Mohammad |
author_facet | Ghasemi, Darioush Araeynejad, Faridoddin Maghsoud, Omid Gerami, Nafiseh Keihan, Amir Homayoun Rezaie, Ehsan Mehdizadeh, Saber Hosseinzadeh, Ramin Mohammadi, Ramtin Bahardoust, Mansour Heiat, Mohammad |
author_sort | Ghasemi, Darioush |
collection | PubMed |
description | SARS-CoV-2 is a newly emerged coronavirus that has been widely transmitted since late 2019. It has caused a pandemic and infected roughly 450 million people globally.Hitherto, there is no approved anti-COVID-19 treatment, and vaccination is the only experienced preventive strategy. It mainly promotes the immune system, which is vital as a barrier against COVID-19. Humoral immunity (antibody-mediated immunity), among the various functions of the immune system against the coronavirus, plays an outstanding role in preventing infection. Consequently, we intended to assess IgG and IgM antibodies, 3 and 6 months after infection, to trend their titer and see how long COVID-19 antibodies remained in the human body. According to the research-designed criteria, only 98 patients out of 4500 suspected cases of SARS-CoV-2 infection remained for analysis. Blood samples were taken in three time periods (Day Zero (T(0)), 3 and 6 months post-infection) and examined for COVID-19’s IgG and IgM antibodies titration using the ELISA platform. Though both IgG and IgM were still detectable for some subjects at the end of the period, the decline in their levels (from 14.45 ± 5.88 to 2.52 ± 2.33 for IgG [85% decline of antibody titer] and 8.3 ± 0.99 to 0.37 ± 0.14 for IgM [95.5% decline of antibody titer]) was statistically significant (P value 0.0001). There was no correlation between gender and IgG and IgM levels. Although the levels of both antibodies were overall higher in the senior group (≥ 60 years old), statistical analysis showed a significantly higher level just for IgM in this group (P value: 0.005). Following the results, although anti-SARS-CoV-2 IgM and IgG antibodies can persist in the blood for 6 months post-infection, their levels steeply declined over time. Therefore, relying on humoral immunity as a trustworthy barrier against SARS-CoV-2 infection calls for more extensive research. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40995-022-01382-7. |
format | Online Article Text |
id | pubmed-9702912 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-97029122022-11-28 The Trend of IgG and IgM Antibodies During 6-Month Period After the Disease Episode in COVID-19 Patients Ghasemi, Darioush Araeynejad, Faridoddin Maghsoud, Omid Gerami, Nafiseh Keihan, Amir Homayoun Rezaie, Ehsan Mehdizadeh, Saber Hosseinzadeh, Ramin Mohammadi, Ramtin Bahardoust, Mansour Heiat, Mohammad Iran J Sci Technol Trans A Sci Research Paper SARS-CoV-2 is a newly emerged coronavirus that has been widely transmitted since late 2019. It has caused a pandemic and infected roughly 450 million people globally.Hitherto, there is no approved anti-COVID-19 treatment, and vaccination is the only experienced preventive strategy. It mainly promotes the immune system, which is vital as a barrier against COVID-19. Humoral immunity (antibody-mediated immunity), among the various functions of the immune system against the coronavirus, plays an outstanding role in preventing infection. Consequently, we intended to assess IgG and IgM antibodies, 3 and 6 months after infection, to trend their titer and see how long COVID-19 antibodies remained in the human body. According to the research-designed criteria, only 98 patients out of 4500 suspected cases of SARS-CoV-2 infection remained for analysis. Blood samples were taken in three time periods (Day Zero (T(0)), 3 and 6 months post-infection) and examined for COVID-19’s IgG and IgM antibodies titration using the ELISA platform. Though both IgG and IgM were still detectable for some subjects at the end of the period, the decline in their levels (from 14.45 ± 5.88 to 2.52 ± 2.33 for IgG [85% decline of antibody titer] and 8.3 ± 0.99 to 0.37 ± 0.14 for IgM [95.5% decline of antibody titer]) was statistically significant (P value 0.0001). There was no correlation between gender and IgG and IgM levels. Although the levels of both antibodies were overall higher in the senior group (≥ 60 years old), statistical analysis showed a significantly higher level just for IgM in this group (P value: 0.005). Following the results, although anti-SARS-CoV-2 IgM and IgG antibodies can persist in the blood for 6 months post-infection, their levels steeply declined over time. Therefore, relying on humoral immunity as a trustworthy barrier against SARS-CoV-2 infection calls for more extensive research. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40995-022-01382-7. Springer International Publishing 2022-11-28 2022 /pmc/articles/PMC9702912/ /pubmed/36466050 http://dx.doi.org/10.1007/s40995-022-01382-7 Text en © The Author(s), under exclusive licence to Shiraz University 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Research Paper Ghasemi, Darioush Araeynejad, Faridoddin Maghsoud, Omid Gerami, Nafiseh Keihan, Amir Homayoun Rezaie, Ehsan Mehdizadeh, Saber Hosseinzadeh, Ramin Mohammadi, Ramtin Bahardoust, Mansour Heiat, Mohammad The Trend of IgG and IgM Antibodies During 6-Month Period After the Disease Episode in COVID-19 Patients |
title | The Trend of IgG and IgM Antibodies During 6-Month Period After the Disease Episode in COVID-19 Patients |
title_full | The Trend of IgG and IgM Antibodies During 6-Month Period After the Disease Episode in COVID-19 Patients |
title_fullStr | The Trend of IgG and IgM Antibodies During 6-Month Period After the Disease Episode in COVID-19 Patients |
title_full_unstemmed | The Trend of IgG and IgM Antibodies During 6-Month Period After the Disease Episode in COVID-19 Patients |
title_short | The Trend of IgG and IgM Antibodies During 6-Month Period After the Disease Episode in COVID-19 Patients |
title_sort | trend of igg and igm antibodies during 6-month period after the disease episode in covid-19 patients |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702912/ https://www.ncbi.nlm.nih.gov/pubmed/36466050 http://dx.doi.org/10.1007/s40995-022-01382-7 |
work_keys_str_mv | AT ghasemidarioush thetrendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT araeynejadfaridoddin thetrendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT maghsoudomid thetrendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT geraminafiseh thetrendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT keihanamirhomayoun thetrendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT rezaieehsan thetrendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT mehdizadehsaber thetrendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT hosseinzadehramin thetrendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT mohammadiramtin thetrendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT bahardoustmansour thetrendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT heiatmohammad thetrendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT ghasemidarioush trendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT araeynejadfaridoddin trendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT maghsoudomid trendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT geraminafiseh trendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT keihanamirhomayoun trendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT rezaieehsan trendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT mehdizadehsaber trendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT hosseinzadehramin trendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT mohammadiramtin trendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT bahardoustmansour trendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients AT heiatmohammad trendofiggandigmantibodiesduring6monthperiodafterthediseaseepisodeincovid19patients |